Major pharmaceutical companies and CMOs in the US have announced emergency contingency plans, including facility closures and the relocation of drug products, as Hurricane Florence approaches southeastern shores.
The US Food and Drug Administration (FDA) has sent Merck & Co a
warning letter saying it has failed to correct a number of
manufacturing deficiencies at its main vaccine manufacturing plant
in West Point, Pennsylvania.
Lower than expected yields of varicella zoster virus (VZV) have
forced Merck & Co to run down US supplies of ProQuad, its
all-in-one children's vaccine for measles, mumps, rubella (German
measles) and varicella (chickenpox).
Drug giant Merck & Co has seen flat sales and a rise in
operating costs in the first quarter of 2006, as its restructuring
initiative, which contract manufacturers welcomed, takes its toll
on the company.
Merck & Co said it would cut an additional $1 billion (€832
million) through 2010 as it struggles to regain R&D momentum
after mounting lawsuits, generic competition and falling revenue
and profit threaten to engulf the company,...
Merck & Co, still reeling from the impact of pulling its
painkiller Vioxx (rofecoxib) from the market, is to slash its staff
by 5,100 positions in a bid to save hundreds of millions of dollars
by the end of the year.
A new study suggests that there are important differences between
Merck & Co's Vioxx (rofecoxib) and other COX-2 inhibitors and
that this may account for variations in cardiovascular safety
within this drug class, writes...